Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Surgical Science Sweden
132
SEK
−1,27 %
Alle 1K seuraajaa
SUS
First North Stockholm
Medical Equipment & Services
Health Care
Yleiskuva
Luvut & ennusteet
Omistajat
−1,27%
−25,59%
−15,33%
−12,58%
+10,09%
−8,4%
−29,79%
+134,88%
+1 047,83%
Surgical Science Sweden is a medical technology company. The company develops VR simulators in surgery. The simulators consist of both hardware and software used in training and personal development by surgeons. The hardware simulates various surgical procedures, with mainly use in peephole surgery and endoscopy. The vision is to strengthen the competence in surgery and create conditions for better treatments. The company is headquartered in Gothenburg.
Lue lisääMarkkina-arvo
6,74 mrd. SEK
Vaihto
21,14 milj. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Pörssikalenteri
14.5.
2025
Osavuosikatsaus Q1'25
15.5.
2025
Yhtiökokous '25
21.8.
2025
Osavuosikatsaus Q2'25
Kaikki
Webcastit
Tiedotteet
NäytäKaikki sisältötyypit

Surgical Science Sweden, Audiocast with teleconference, Q4'24
Year-end report 2024: STRONG END TO THE YEAR
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Scheme of Arrangement Effective in relation to the Recommended Offer to Acquire Intelligent Ultrasound
Results of Shareholder Meetings in relation to the Recommended Offer to Acquire Intelligent Ultrasound
Conference call regarding Year-end report 2024
Surgical Science wins a procurement contract in Southeast Asia amounting to SEK 52 million – new product and new customer group
Proposal for election of the board of Surgical Science Sweden AB (publ)
Surgical Science is transitioning to a fully subscription-based revenue model with Intuitive and all da Vinci 5* systems will be equipped with Surgical Science simulation software
Publication of Scheme Document in relation to the Recommended Offer to Acquire Intelligent Ultrasound

Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
Surgical Science Announces Recommended Offer to Acquire Intelligent Ultrasound
Redeye: Surgical Science Q3 2024 - Sequential improvements continue

Surgical Science Sweden, Audiocast with teleconference, Q3'24
Interim report January – September 2024: 12% CURRENCY-NEUTRAL INCREASE IN SALES
Conference call regarding interim report Q3
Nomination Committee of Surgical Science Sweden AB (publ)
Tom Englund takes over as the new CEO of Surgical Science
Redeye: Surgical Science Q2 2024 - Solid sequential recovery, decent outlook
